By Pol Allingham

Doctors have praised “unprecedentedly strong responses” to an injection that eradicated entire tumours in otherwise treatment-resistant cancer cases during a trial.

It shrank the tumours for 42 per cent of patients in the Institute of Cancer Research, London, international study.

Scientists gave amivantamab to people with recurrent and/or metastatic head and neck cancer who had stopped responding to standard treatments.

Amivantamab is a small injection, unlike many cancer medications that require intravenous drips.

One participant with tongue cancer said the treatment reduced his pain and swelling, and he is no longer experiencing the “life-impacting” side effects he had during chemotherapy.

Kevin Harrington, professor in biological cancer therapies at the institute and consultant oncologist at The Royal Marsden NHS Foundation Trust, hailed the treatment.

“These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy,” he said.

“This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking.”

“This treatment has the potential to benefit many thousands of patients each year.”

Head and neck cancer is the sixth most common cancer worldwide.

This phase of the OrigAMI-4 trial looked at 102 people with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), whose cancer had continued to grow despite immunotherapy and platinum-based chemotherapy.

The patients, from 55 hospitals in 11 countries, only received amivantamab, which is being developed by Johnson & Johnson.

Tumours shrank in 43 participants – 15 had them disappear completely and 28 saw their tumours shrink significantly.

Patients with amivantamab lived for a median of 12.5 months after starting the treatment, despite having a cancer type with “very poor outcomes” once standard treatments stop working, the ICR said.

Tumours started to respond within about six weeks and patients had a median of a little more than six-and-a-half months before the cancer started to grow again, it found.

Carl Walsh, 56, from Birmingham, was diagnosed with tongue cancer in May 2024 and joined the study at The Royal Marsden in July 2025 after chemotherapy and immunotherapy were both unsuccessful.

“I now feel able to live a normal life. Before starting the trial, I struggled to speak properly and found eating difficult because of the swelling and pain,” he said in a statement released by the ICR.

“Since beginning treatment, the swelling has reduced significantly, and my pain levels have improved considerably.

“I’m also no longer experiencing the same life-impacting side effects that I had during chemotherapy.”

The drug is called a bispecific monoclonal antibody and it blocks two signals: EGFR (Epidermal Growth Factor Receptor) which is a protein that helps tumours grow; and MET, a separate pathway often used by cancer cells to escape treatment.

It also has a third benefit: helping to activate the immune system to attack the tumour.

The fact it is an injection makes it faster, more convenient for patients, and “significantly easier” to deliver in outpatients clinics, the ICR said.

Amivantamab is given every three weeks and side effects were mild to moderate.

Fewer than 10 patients stopped treatment because of side effects.

Professor Kristian Helin, chief executive of the ICR, said “the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options”.

“Achieving this level of tumour response and encouraging survival outcomes in such a challenging to treat group represents a significant step forward.”

Amivantamab has already been approved for multiple subtypes of lung cancer across multiple lines of therapy.

The study is being presented to the American Society of Clinical Oncology.

IMPORTANT LEGAL INFO This article is of a general nature and FYI only, because it doesn’t take into account your personal health requirements or existing medical conditions. That means it’s not personalised health advice and shouldn’t be relied upon as if it is. Before making a health-related decision, you should work out if the info is appropriate for your situation and get professional medical advice.